Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1996, for Cheung Laboratories, Inc. (Note: The request metadata listed "Imunon, Inc.", but the filing text explicitly identifies the registrant as Cheung Laboratories, Inc.). The company develops minimally invasive medical devices for cancer and benign prostatic hyperplasia (BPH) treatment, specifically the Microfocus 1000 and Microfocus 800 systems. The company is currently in the engineering and regulatory approval stages for new technologies, including Adaptive Phased Array (APA) and compression technology.
Key Financial Metrics
| Metric | Q1 FY1997 (Ended Dec 31, 1996) | Q1 FY1996 (Ended Dec 31, 1995) |
|---|---|---|
| Total Revenue | $94,040 | $1,000 |
| Gross Profit | $62,177 | $555 |
| Net Loss | $(438,257) | $(253,200) |
| Net Loss Per Share | $(0.017) | $(0.006) |
| Cash and Equivalents (Ending) | $9,807 | $24,555 |
| Accumulated Deficit | $(12,649,890) | $(12,211,633) |
| Total Liabilities | $2,774,732 | N/A (Balance Sheet not provided for 1995) |
| Stockholders' Equity | $(1,653,701) | N/A |
Operating Cash Flow: Net cash used in operating activities was $(268,475) for the quarter ended December 31, 1996, compared to $(199,210) in the prior year period.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $1,000 to $94,040, driven by increased sales of Microfocus products.
- Expense Growth: Operating expenses rose to $438,510 from $233,664. Selling, general, and administrative (SG&A) expenses increased to $396,276 due to restructuring activities. R&D expenses jumped to $42,234 from $7,610 due to technology enhancement efforts.
- Capital Structure: The company redeemed and retired 16,000,000 shares of common stock in October 1996 by rescinding its equity interest in Aestar Fine Chemical Company. This reduced outstanding shares from 41.2 million (Sept 1996) to 25.3 million (Dec 1996).
- Liquidity Decline: Cash balances dropped significantly from $246,931 at the beginning of the quarter to $9,807 at period end.
Outlook, Risks, and Management Commentary
- Liquidity Risk: Management explicitly states that existing capital resources will not be adequate to fund operations for the next twelve months. The company is dependent on raising additional capital through equity or debt financing.
- Regulatory Hurdles: The company lacks FDA Investigational Device Exemption (IDE) or Pre-Market Approval (PMA) for its BPH system (Microfocus 800) and the new Microfocus APA device. Commercial sales in the U.S. are contingent on these approvals.
- Subsequent Event: On January 7, 1997, the company offered $300,000 in new convertible notes and attempted to rescind $1,205,000 in existing notes. As of February 13, 1997, the rescission for $1,090,000 was rejected, while $115,000 was rescinded and refunded.
- Strategic Focus: The company plans to significantly increase R&D expenditures to incorporate APA and MMTC technologies and expand marketing efforts.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure immediate financing given the $9,807 cash balance and management's admission of insufficient funds for the next 12 months.
- Debt Status: Confirm the final status of the $1,205,000 in private placement notes following the partial rejection of the rescission offer.
- Regulatory Timeline: Assess the timeline for obtaining FDA IDE and PMA approvals for the Microfocus APA and Microfocus 800 devices, as revenue growth is tied to these milestones.
- Share Count: Note the significant reduction in outstanding shares (from 41.2M to 25.3M) due to the Aestar transaction and its impact on per-share metrics.